TP53 and leukemia: To further evaluate intratumoral heterogeneity in TP53/TET2 comutant AML, we further fragmented AML clusters 3 and 6 and identified 5 distinct clusters of AML cells, including OXPHOShi, IFNhi, hyperproliferative, neutrophil-like, and erythroid-like AML populations (Figure 6, D and E) (22).The IFNhi AML population displayed enrichment in myeloid suppressor cell markers, macrophage myeloid differentiation markers (Ccl6), the eosinophil IgE receptor (Fcer1g), and Cd52, which is highly expressed on leukemia progenitor cells (Figure 6E).